Summary:
A 12-week, randomized, open-label Iloperidone flexible dose study assessing efficacy, safety and tolerability for those currently receiving risperidone, olanzapine or aripiprazole.
Qualified Participants Must:
• Have been diagnosed with Schizophrenia and are taking Risperidone, (Risperdal), Olanzapine (Zyprexa) or Aripiprazole (Abilify)
•
Be 18-64 years of age
Qualified Participants May Receive:
All medical treatment and study drug at no cost.